149 related articles for article (PubMed ID: 32801773)
1. Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma.
Yang L; Dao FT; Chang Y; Wang YZ; Li LD; Chen WM; Long LY; Liu YR; Lu J; Liu KY; Qin YZ
Onco Targets Ther; 2020; 13():7545-7553. PubMed ID: 32801773
[TBL] [Abstract][Full Text] [Related]
2. Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.
Qin YZ; Zhang YH; Qin XY; Zhu HH
Oncol Lett; 2017 Apr; 13(4):2823-2830. PubMed ID: 28454473
[TBL] [Abstract][Full Text] [Related]
3. PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.
Yang L; Wang YZ; Zhu HH; Chang Y; Li LD; Chen WM; Long LY; Zhang YH; Liu YR; Lu J; Qin YZ
DNA Cell Biol; 2017 Dec; 36(12):1099-1107. PubMed ID: 28953414
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
Qin Y; Lu J; Bao L; Zhu H; Li J; Li L; Lai Y; Shi H; Wang Y; Liu Y; Jiang B; Huang X
Chin Med J (Engl); 2014; 127(9):1666-71. PubMed ID: 24791872
[TBL] [Abstract][Full Text] [Related]
5. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
[TBL] [Abstract][Full Text] [Related]
6. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
[TBL] [Abstract][Full Text] [Related]
7. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
9. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
10. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
[TBL] [Abstract][Full Text] [Related]
11. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
Schenk T; Stengel S; Goellner S; Steinbach D; Saluz HP
Genes Chromosomes Cancer; 2007 Sep; 46(9):796-804. PubMed ID: 17534929
[TBL] [Abstract][Full Text] [Related]
13. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
14.
Pankov D; Sjöström L; Kalidindi T; Lee SG; Sjöström K; Gardner R; McDevitt MR; O'Reilly R; Thorek DLJ; Larson SM; Veach D; Ulmert D
Oncotarget; 2017 Sep; 8(39):65917-65931. PubMed ID: 29029482
[TBL] [Abstract][Full Text] [Related]
15. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.
Roszik J; Wang WL; Livingston JA; Roland CL; Ravi V; Yee C; Hwu P; Futreal A; Lazar AJ; Patel SR; Conley AP
Clin Sarcoma Res; 2017; 7():11. PubMed ID: 28630682
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
[TBL] [Abstract][Full Text] [Related]
17. Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes.
Kaczorowski M; Lasota J; Dudek K; Małkiewicz B; Miettinen M; Hałoń A
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541782
[No Abstract] [Full Text] [Related]
18. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
19. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
20. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia.
Matsushita M; Ikeda H; Kizaki M; Okamoto S; Ogasawara M; Ikeda Y; Kawakami Y
Br J Haematol; 2001 Mar; 112(4):916-26. PubMed ID: 11298586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
